In a phase 1 trial of pembrolizumab in the treatment of 10 Japanese patients with advanced solid tumors including NSCLC, melanoma, and breast cancer, grade 3 alanine transaminase (ALT) elevation, grade 3 aspartate transaminase (AST) elevation, grade 1 pneumonitis, and grade 1 thyroid-stimulating hormone (TSH) elevation were reported as irAEs (Shimizu et al., 2016). This evidence concerns the gene GPT and pneumonitis.